What Researchers Did
Researchers conducted a retrospective cohort study of 70 patients with idiopathic sudden sensorineural hearing loss (ISSNHL) to evaluate the effectiveness and optimal timing of hyperbaric oxygen therapy (HBOT) in conjunction with steroid treatment.
What They Found
Patients receiving early HBOT (within 12 days) showed the greatest median hearing improvement of 33.8 dB, significantly more than late HBOT (6.9 dB), salvage HBOT (0.0 dB), or no HBOT (11.9 dB). Treatment initiated within 10.5 days strongly predicted marked improvement, with each day's delay reducing pure-tone audiometry improvement by 0.832 dB.
What This Means for Canadian Patients
Canadian patients experiencing idiopathic sudden sensorineural hearing loss (ISSNHL) may benefit significantly from hyperbaric oxygen therapy (HBOT). Seeking this treatment as early as possible, ideally within 10 days of onset, could lead to substantially better hearing recovery.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.
Study Limitations
As a retrospective cohort study with a relatively small sample size, this study may be subject to selection bias and unmeasured confounding factors.